<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>血管造影 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/xueguanzaoying/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Thu, 09 Dec 2021 08:04:53 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>血管造影 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国碘海醇市场研究报告(2020年销售额达6.91亿元)</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguodianhaichunshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Mon, 21 Jun 2021 06:46:00 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[ERC]]></category>
		<category><![CDATA[IVP]]></category>
		<category><![CDATA[PTC]]></category>
		<category><![CDATA[“T”行管道造影]]></category>
		<category><![CDATA[关节腔造影]]></category>
		<category><![CDATA[典可]]></category>
		<category><![CDATA[内窥镜逆行胰胆管造影]]></category>
		<category><![CDATA[冠状动脉造影]]></category>
		<category><![CDATA[北陆药业]]></category>
		<category><![CDATA[双北]]></category>
		<category><![CDATA[周围及内脏动脉造影]]></category>
		<category><![CDATA[头部及体部CT增强造影]]></category>
		<category><![CDATA[心室造影]]></category>
		<category><![CDATA[扬子江药业]]></category>
		<category><![CDATA[枢刻明]]></category>
		<category><![CDATA[欧乃派克]]></category>
		<category><![CDATA[欧苏]]></category>
		<category><![CDATA[汉森制药]]></category>
		<category><![CDATA[疝或瘘道造影]]></category>
		<category><![CDATA[碘海淳]]></category>
		<category><![CDATA[经皮经肝胆管造影]]></category>
		<category><![CDATA[胃肠道造影]]></category>
		<category><![CDATA[脑血管造影]]></category>
		<category><![CDATA[血管造影]]></category>
		<category><![CDATA[通用电气药业(上海)有限公司]]></category>
		<category><![CDATA[造影剂]]></category>
		<category><![CDATA[金健药业]]></category>
		<category><![CDATA[静脉尿路造影]]></category>
		<category><![CDATA[非离子型X线造影剂]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24382</guid>

					<description><![CDATA[碘海醇是一种非离子型X线造影剂。CRI元哲的调研数据显示，2016-2019年中国市场的碘海醇销售额逐年增长。2020年由于新冠疫情对医院整体诊疗服务造成了冲击，其中国市场的碘海醇销售额减少到6.91亿元，同比下降13.53%。2016-2020年中国市场的碘海醇销售额的CAGR为0.45%。CRI元哲预计在2021-2025年随着新冠疫情的缓解，中国市场碘海醇销售额将有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
